Question-and-Answer Session
Operator
(Operator Instructions). And the first question comes from the line of Adam Feinstein from Barclays Capital. Please proceed.
Adam Feinstein - Barclays Capital
Alright, thank you very much. Good morning everyone, very strong quarter. Just wanted to just ask few questions here, I guess it seems like everything is going well with the consolidation in the synergies. Just as you think of your synergies do you have a cumulative number in terms of what percent you have hit that far?
Mike Culotta
Adam, this is Mike. I think one of the things to look at really is to look back historically what was the run rate that this company had and the run rate when you look at everything that's been disclosed. The run rate was roughly around $62 million to $65 million and when you look -- let's just use the upper limit of our guidance and you look at our upper limit which is roughly about $92 million and you take the difference between those two since the time that the companies by now.
We've improved operation $30 million, at the same time that's roughly decline in beds, net beds of about 15,000 with no acquisition. So, when you really step down and you take a look at it. We right now are looking at right now at the $30 million and again that includes some inefficiencies that we had throughout the year so. Again when you take a look at it from a global area we've hit the 30 million.
Adam Feinstein - Barclays Capital
Yes, I know it certainly. Certainly it seems very, very strong. And then just as you think about just this product mix in the quarter, just curious was there a significant change in terms of your generic mix and just curious in terms of on some of the new products such as Risperdal in terms of the impact, some of that may impact in the quarter.
Greg Weishar
Well I'll take that one. But clearly we -- Adam we've seen growth in our generics, continue to see growth in our generics. In terms of Risperdal it came out as an exclusive and looks like that's going to be changing this month. But I don't think there are any surprises; we thought that Depakote sprinkles might get out before it did, but obviously that didn't happen there, it looks like its going to come out this quarter, the fourth quarter. But I would say there were no surprises there.
- To read the full transcript on Seeking Alpha, click here »
